Research material comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
The original endogenous chemistry was also found in MOR 1125 based on preservation of elements associated with bone remodeling and redeposition (sulfur, calcium, zinc), which showed that the bone cortices are similar to those of extant birds. In studies reported in Science in April 2007, Asara and colleagues concluded that seven traces of collagen proteins detected in purified T. rex bone most closely match those reported in chickens, followed by frogs and newts. The discovery of proteins from a creature tens of millions of years old, along with similar traces the team found in a mastodon bone at least 160,000 years old, upends the conventional view of fossils and may shift paleontologists' focus from bone hunting to biochemistry. Until these finds, most scientists presumed that fossilization replaced all living tissue with inert minerals. Paleontologist Hans Larsson of McGill University in Montreal, who was not part of the studies, called the finds "a milestone", and suggested that dinosaurs could "enter the field of molecular biology and really slingshot paleontology into the modern world". The presumed soft tissue was called into question by Thomas Kaye of the University of Washington and his co-authors in 2008. They contend that what was really inside the tyrannosaur bone was slimy biofilm created by bacteria that coated the voids once occupied by blood vessels and cells. The researchers found that what previously had been identified as remnants of blood cells, because of the presence of iron, were actually framboids, microscopic mineral spheres bearing iron.
In 1998, an initial observational trial demonstrated the effectiveness of intravenous pamidronate, a bisphosphonate which had previously been used in adults to treat osteoporosis. In severe OI, this trial showed that pamidronate reduced bone pain, prevented new vertebral fractures, reshaped previously fractured vertebral bodies, and reduced the number of long-bone fractures. Although oral bisphosphonates are more convenient and cheaper, they are not absorbed as well, and intravenous bisphosphonates are generally more effective, although this is under study. Some studies have found oral and intravenous bisphosphonates, such as oral alendronate and intravenous pamidronate, equivalent. In a 2013 double-blind trial of children with mild OI, oral risedronate increased bone mineral densities, and reduced nonvertebral fractures. However, it did not decrease new vertebral fractures. A Cochrane review in 2016 concluded that though bisphosphonates seem to improve bone mineral density, it is uncertain whether this leads either to a reduction in bone fractures or improvement in the quality of life of individuals with osteogenesis imperfecta. Even in trials with as many as 125 children, no causal link has been found between bisphosphonates and decreased fracture rates; placebo controlled trials were also unable to prove that they brought about increased strength, motor control or lower pain levels. Bisphosphonates are not as effective at increasing the bone mineral density of adults.
Fibrils (from Latin fibra) are structural biological materials found in nearly all living organisms. Not to be confused with fibers or filaments, fibrils tend to have diameters ranging from 10 to 100 nanometers (whereas fibers are micro to milli-scale structures and filaments have diameters approximately 10–50 nanometers in size). Fibrils are not usually found alone but rather are parts of greater hierarchical structures commonly found in biological systems. Due to the prevalence of fibrils in biological systems, their study is of great importance in the fields of microbiology, biomechanics, and materials science.
Twenty isotopes and six nuclear isomers (excited states of an isotope) of berkelium have been characterized, with mass numbers ranging from 233 to 253 (except 237). All of them are radioactive. The longest half-lives are observed for 247Bk (1,380 years), 248Bk (unknown, almost surely over 300 years), and 249Bk (327.2 days); other isotopes are less than a week. The isotope which is the easiest to synthesize (reactor neutron capture) is berkelium-249. This emits mostly soft β-particles which are inconvenient for detection. Its alpha radiation is rather weak (1.45×10−3%) with respect to the β-radiation, but is sometimes used to detect this isotope. The second important berkelium isotope, berkelium-247, is beta-stable and an alpha emitter, as are most long-lived actinide isotopes.
=== Manufacture === Merck KGaA currently relies on third-party manufacturers to supply the product candidate: On Baxter International for the manufacture of tecemotide, and on GlaxoSmithKline plc (GSK) for the manufacture of the adjuvant in tecemotide, monophosphoryl lipid A (MPL). As of 2013, there was a risk that if tecemotide were not approved by 2015, GSK could terminate its obligation to supply MPL. In this case, Oncothyreon would have had to retain the necessary licenses from GSK required to have the adjuvant MPL manufactured, but the transfer of the process to a third party would delay the development and commercialization of tecemotide.
Sources: en.wikipedia.org
Zhang's tactics included propaganda, intelligence-gathering, and involvement in the opium trade, while Liu fought back with counter-propaganda and appointing loyalist magistrates who frustrated Zhang's work. Liu triumphed in 1942 when the 36th Division was moved to the Yunnanese front, and Zhang was transferred back to Chongqing in 1946. Zhang's presence was replaced by He Guoguang, but Liu continued frustrating Nationalist centralization attempts. In 1944 during Operation Ichi-Go, there was once again talk of moving the capital to Xichang, encouraged by American General Wedermeyer, but this was abandoned after the Japanese offensive stalled. In late 1942, Chiang ordered Liu and Ma Bufang of Qinghai to mobilize for a campaign against Tibet. Liu was suspicious of the Nationalist leader's motivations, dispatching his chief of staff Wu Peiying (伍培英) to Chongqing to plan for the invasion and negotiate with Chiang. According to Liu's 1990 biography, he had asked for a fully-equipped division of 10,000 troops, cavalry, and engineers; another division to maintain order, winter equipment, around 10,000 yaks, additional food supplies, and a truck route from Sichuan to Xikang. Liu also requested that he take sole command of these reinforcements. Later archival documents would confirm Liu's suspicions that the campaign was a plot; once Liu had mobilized his forces, Chiang was to send 30,000 men under his personal command into Xikang and depose Liu. Due to Liu's stalling tactics as well as Allied pressure, the campaign did not materialize.
== Mycelium-based textiles == Mycelium, the vegetative part of fungi, has emerged as a versatile and sustainable raw material for biotextiles. Mycelium typically grows underground or within its substrate such as soil, wood, decaying organic matter or waste residues. In mycelium-based biocomposites, the fungus consumes the carbohydrates to produce hyphae, a network of branching, thread-like structures. Through controlled growth processes, mycelium can be cultivated into a dense network of interwoven fibers, forming a durable biodegradable matrix suitable for textile applications. This cultivation depends on the temperature, moisture and pH of the media.
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-alanine:NAD+ oxidoreductase (deaminating). Other names in common use include AlaDH, L-alanine dehydrogenase, NAD+-linked alanine dehydrogenase, alpha-alanine dehydrogenase, NAD+-dependent alanine dehydrogenase, alanine oxidoreductase, and NADH-dependent alanine dehydrogenase. T
== Alternatives == While being one of the more precise and low-cost protein separation and analysis methods, the SDS-PAGE denatures proteins. Where non-denaturing conditions are necessary, proteins are separated by a native PAGE or different chromatographic methods with subsequent photometric quantification, for example affinity chromatography (or even tandem affinity purification), size exclusion chromatography, ion exchange chromatography. Proteins can also be separated by size in a tangential flow filtration or an ultrafiltration. Single proteins can be isolated from a mixture by affinity chromatography or by a pull-down assay. Some historically early and cost effective but crude separation methods usually based upon a series of extractions and precipitations using kosmotropic molecules, for example the ammonium sulfate precipitation and the polyethyleneglycol precipitation.
Sources: en.wikipedia.org
=== Mass spectral quality === A key feature of this interface is to produce top quality EI spectra from compounds dissolved in a liquid phase. In this case, quality is intended as a measure of the degree of success in a virtual comparison with thousands of spectra stored in the electronic libraries. Identification capability in real-world applications, when peaks are small and noise is high, can be greatly influenced by the quality of ionization. A NIST library version 2.0d was used for comparison. In this case, identification capability is not compromised by the presence of solvent vapor residues and matching quality tops that of a typical GC-MS system.
In regions such as the gingiva and parts of the hard palate, oral mucosa is attached directly to the periosteum of underlying bone, with no intervening submucosa. This arrangement is called a mucoperiosteum and provides a firm, inelastic attachment. A variable number of Fordyce spots or granules are scattered throughout the nonkeratinized tissue. These are a normal variant, visible as small, yellowish bumps on the surface of the mucosa. They correspond to deposits of sebum from misplaced sebaceous glands in the submucosa that are usually associated with hair follicles. A basal lamina (basement membrane without aid of the microscope) is at the interface between the oral epithelium and lamina propria similar to the epidermis and dermis.
However, the direct calorimetric method generally overestimates the actual energy that the body can obtain from the food, because it also counts the energy contents of dietary fiber and other indigestible components, and does not allow for partial absorption and/or incomplete metabolism of certain substances. For this reason, today the energy content of food is instead obtained indirectly, by using chemical analysis to determine the amount of each digestible dietary component (such as protein, carbohydrates, and fats), and adding the respective food energy contents, previously obtained by measurement of metabolic heat released by the body. In particular, the fibre content is excluded. This method is known as the Modified Atwater system, after Wilbur Atwater who pioneered these measurements in the late 19th century. The system was later improved by Annabel Merrill and Bernice Watt of the USDA, who derived a system whereby specific calorie conversion factors for different foods were proposed.
A humanized mouse is a genetically modified mouse that has functioning human genes, cells, tissues and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. A humanized mouse or a humanized mouse model is one that has been xenotransplanted with human cells and/or engineered to express human gene products, so as to be utilized for gaining relevant insights in the in vivo context for understanding of human-specific physiology and pathologies. Several human biological processes have been explored using animal models like rodents and non-human primates. In particular, small animals such as mice are advantageous in such studies owing to their small size, brief reproductive cycle, easy handling and due to the genomic and physiological similarities with humans; moreover, these animals can also be genetically modified easily. Nevertheless, there are several incongruencies of these animal systems with those of humans, especially with regard to the components of the immune system. To overcome these limitations and to realize the full potential of animal models to enable researchers to get a clear picture of the nature and pathogenesis of immune responses mounted against human-specific pathogens, humanized mouse models have been developed. Such mouse models have also become an integral aspect of preclinical biomedical research.
=== Fetal alcohol spectrum disorder === Fetal alcohol spectrum disorder (FASD), formerly referred to as fetal alcohol syndrome, presents as craniofacial malformations, neurobehavioral disorders and mental disabilities, all attributed to exposing human embryos to alcohol during fetal development. The risk of FASD depends on the amount consumed, the frequency of consumption, and the points in pregnancy at which the alcohol is consumed. Ethanol is a known teratogen, i.e., causes birth defects. Ethanol is metabolized by alcohol dehydrogenase enzymes into acetaldehyde. The subsequent oxidation of acetaldehyde into acetate is performed by aldehyde dehydrogenase enzymes. Given that retinoic acid (RA) regulates numerous embryonic and differentiation processes, one of the proposed mechanisms for the teratogenic effects of ethanol is a competition for the enzymes required for the biosynthesis of RA from vitamin A. Animal research demonstrates that in the embryo, the competition takes place between acetaldehyde and retinaldehyde for aldehyde dehydrogenase activity. In this model, acetaldehyde inhibits the production of retinoic acid by retinaldehyde dehydrogenase. Ethanol-induced developmental defects can be ameliorated by increasing the levels of retinol, retinaldehyde, or retinaldehyde dehydrogenase. Thus, animal research supports the reduction of retinoic acid activity as an etiological trigger in the induction of FASD.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.